Immune cell screening services
Answer questions in biologically relevant primary immune cell types. Leveraging our expertise in screening and receive robust data from high-throughput assays.
Efficiently identify therapeutic candidates that influence the suppression of T effector cells through high-throughput screening, utilizing our extensive expertise. Benefit from our ability to acquire in-vitro data from multiple donors, evaluate the impact of your small molecules or biologics, and advance your project.
| Service description | Number of suitable compounds | Catalog Number |
|---|---|---|
| Standard iTreg Suppression Assay - Mini | 1 to 5 | IMM05-01 |
| Standard iTreg Suppression Assay - Midi | 6 to 11 | IMM05-02 |
| Standard iTreg Suppression Assay - Maxi | 12 to 17 | IMM05-03 |
Standard ImmuSignature™ iTreg suppression assay readouts and cloud-based data report
- T cell viability
- T cell phenotyping for: CD25, CD8 and CD4
- Nine points compound dose response (8 dilutions + vehicle)
- Two iTreg: Teff ratios for mini and midi format. One ratio for maxi size
- Data points set of quadruplicates
- 3-fold dilution range
- All plotted data and raw data files are provided
- Table of EC50s
- Quality control data for cell isolation cells and internal assay controls
Representative data of the iTreg suppression assay
A) Polarization QC of 9 donors on day 7 of polarization with TCR activators and cytokines (polarizing condition) or with TCR activators and IL-2 only (non-polarizing condition). B) CD3+ T effector cells proliferation of 3 independent experiments using three heterologous iTreg donors at a 1:1 ratio (4 replicates per donor). C) Compound dose-response curves of daclizumab antibody and Pam3CSK4 molecule in iTreg suppression assay.
Contact us to discuss your project using the form provided and one of the team will be in touch.
ImmuSignature™ assays: Compound screening in primary immune cells
Rapid in-vitro assessment of therapeutic candidates for immune applications from oncology to autoimmunity
Read our immunology blog
Get the latest insights about the drug discovery tools in the immunology field